Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.

ABSTRACT:

Introduction

The glioblastoma (GBM) immune microenvironment is highly suppressive as it targets and hinders multiple components of the immune system. Checkpoint blockade (CB) is being evaluated for GBM patients. However, biomarker analyses suggest that CB monotherapy may be effective only in a small fraction of GBM patients. We hypothesized that activation of antigen presentation would increase the therapeutic response to PD-1 blockade.

Results

We show that activating DCs through TLR3 agonists enhances the anti-tumor immune response to CB and increases survival in GBM. Mice treated with TLR3 agonist poly(I:C) and anti-PD-1 demonstrated increased DC activation and increased T cell proliferation in tumor draining lymph nodes. We show that DCs are necessary for the improved ant

SUBMITTER: Garzon-Muvdi T 

PROVIDER: S-EPMC5945499 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature